Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Deals this week: Sitryx, Keen Eye, Accera
  2. Deals this week: Enesi Pharma, Telix Pharmaceuticals, Kite
  3. M&As this week: Amicus Therapeutics, Alexion Pharmaceuticals, Tris Pharma
  4. Deals this week: Immutep, Enesi Pharma, LineaRx
  5. Deals and M&As this week: CRISPR, Integral Molecular, Evotec

Latest Content

Secuado

Secuado (asenapine) for the Treatment of Schizophrenia

Secuado® (asenapine) is an atypical anti-psychotic drug approved for the treatment of schizophrenia in adult patients. It is the first drug approved as transdermal patch formulation for schizophrenia treatment in the US.

Soliris – Treatment for PNH, aHUS, gMG, and NMOSD

Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Humira for the Treatment of Hidradenitis Suppurativa

Humira (adalimumab) is a monoclonal antibody indicated for the treatment of more than ten indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), and uveitis.

June’s top news stories

AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).

Latest News

Close
Close
Close

Go Top